Loading...

ARMP ARMATA PHARMACEUTICALS INC Expansion Plans 8-K Filing

RMT

RMP

ARMATA PHARMACEUTICALS INC

(ARMP)

2025 8-K

New Stock Offering

Financial Results Released

Positive Study Results

Corporate Presentation

Product Expansion

Financial Statements

Market Expansion

Annual Meeting Notice

Financial Results

Management Change

Management Changes

Financial Results

Study Enrollment Complete

Management Change

Management Change

Management Appointment

Financial Results

Amendment to Employment Agr...

Annual Meeting of Shareholders

Earnings Reports

Annual Meeting Announcement

Financial Results Announcement

Credit Agreement with Innov...

Promotion of Richard Rychlik

Earnings Reports

Annual Meeting Announcement

Earnings Reports

Management Changes

External Links:

Armata Pharmaceuticals, Inc. reported positive results from its Phase 2a diSArm study of AP-SA02 for treating complicated Staphylococcus aureus bacteremia on October 22, 2025, which were presented at IDWeek 2025.

AI Assistant

ARMATA PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.